Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2024 Nov;20(9):490-510.
doi: 10.1016/j.reumae.2024.10.003. Epub 2024 Nov 5.

Clinical Practice Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus: 2024 Update

Affiliations
Free article
Practice Guideline

Clinical Practice Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus: 2024 Update

Lilia Andrade-Ortega et al. Reumatol Clin (Engl Ed). 2024 Nov.
Free article

Abstract

Herein we present the update for the Mexican Guidelines for the Treatment of Systemic Lupus Erythematosus. It involves the participation of several experts along the country, following the GRADE system. We included aspects regarding vaccines, pregnancy and cardiovascular risk which were not presented in the previous guidelines in 2017.

Keywords: Guidelines; Guías de práctica clínica; Lupus eritematoso sistémico; Systemic lupus erythematosus; Tratamiento; Treatment.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest Deshire Alpizar-Rodriguez has undertaken previous work with GSK Mexico. Lilia Andrade-Ortega has been a speaker, or advisor, for Astra Zeneca and GSK. Sandra M. Carrillo-Vázquez has served as a lecturer for Abbvie, Asofarma, AstraZeneca, GSK, Novartis, and UCB. Sergio Durán-Barragán has been a speaker for Amgen, Janssen, Novartis, and Abbvie, as well as principal investigator in clinical trials with Lilly, Janssen, Novartis, Pfizer, Glaxo, Abbvie, Biogen, BMS, Astra Zeneca, Merck Serono, and UCB. Fedra Irazoque-Palazuelos has been a consultant and speaker for Abbvie, Lilly, and Janssen. Javier Merayo-Chalico has served as a speaker for Abbvie, Astra Zeneca, and Janssen. Sandra Sicsik-Ayala has been a speaker for Abbvie, Lilly, UCB, Janssen, and Roche. Luis H. Silveira has served as speaker for Johnson & Johnson, Teva, and Novartis. Daniel Xibillé-Friedmann has been a speaker and consultant for Astra Zeneca and Lilly, and conducted clinical trials with BMS and IDORSIA. The other authors have no conflict of interests to declare.

Publication types

Substances